{"url_path":"/sec/nxtc/8-k/2026-06-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ****Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1661059/0001104659-26-068604-index.html","accession_number":"0001104659-26-068604","cik":"0001661059","ticker":"NXTC","issuer_name":"NextCure, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1661059/0001104659-26-068604-index.html","primary_entity_key":"0001661059","primary_entity_name":"NextCure, Inc."},"word_count":237,"has_tables":true,"body_markdown":"**Item 7.01****Regulation FD Disclosure**\n\n​\n\nOn June 1, 2026, NextCure, Inc. (“Company”) issued a press release announcing the presentation of a poster containing Phase 1 dose escalation data for its investigational drug candidate SIM0505, such presentation occurring at the American Society for Clinical Oncology 2026 conference (“ASCO 2026”) in Chicago, IL, on June 1, 2026.  \n\nA copy of the Company press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the ASCO 2026 poster is furnished as Exhibit 99.2 to this Current Report on Form 8-K.\n\nOn June 1, 2026, Company updated its corporate presentation to reflect pipeline updates and interim phase 1 data from its ongoing clinical trial for SIM0505.  Beginning on June 1, 2026, Company will be engaging with members of the investment community, which may reference these presentation materials.  \n\nA copy of the Company presentation materials is furnished as Exhibit 99.3 to this Current Report on Form 8-K.\n\nThe information contained in this Item 7.01, including Exhibits 99.1, 99.2, and 99.3, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.\n\n​"}